8月7日，达维塔保健盘中下跌5.01%，报179.23美元/股，成交额1.92亿美元，延续此前跌势。
消息面上，公司Q2调整后每股收益4.02美元超预期，但维持全年EPS指引14.10至15.20美元不变，中值14.65美元低于市场预期的14.88美元，被解读为下半年盈利增速放缓信号。同时，SEC文件显示伯克希尔·哈撒韦出售18.3万股公司股票，美银将目标价设定为170美元，低于当前股价，多重利空持续压制股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.